Q-omics provides the consensus-scored RPP25 profile across patient tissues and cancer cell-line models. RPP25 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPP25 is differentially expressed in 13, with the highest sampling consensus in STAD. Additionally, RPP25 RNA expression shows 16,926 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, STAD, and ACC as cancer lineages where RPP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPP25 survival associations across molecular data types. RPP25 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPP25 RNA expression–survival associations across cancer types. High RPP25 expression shows unfavorable associations in UVM, LUAD, ACC, SKCM and LAML, but favorable associations in CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPP25 RNA expression.
This table summarizes RPP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in STAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPP25 shows lower tumor expression in THCA and higher tumor expression in STAD, BLCA, LUSC, HNSC and COAD. The STAD box plot shows higher RPP25 RNA expression in tumor versus normal tissue (log2 FC = +2.108, t-test p < 0.001).
This table shows molecular features associated with RPP25 in patient tissues and cancer cell lines. In patient samples, RPP25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPP25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and CNS.
